Pharmacoepidemiology

2022 Activity indicators

  • 1 public competitive project led (ISCIII)
  • 2 private projects led
  • 1 contract with public agency led - AEMPS
  • 11 publications
  • IF: 62.89
  • Q1 publications: 4 (36%)
  • D1 publications: 2 (18%)
  • 1 award - best publication in scientific journal.
  • Member of Editorial Committee: 1 PI
  • Member of Evaluation Committee: 1 PI

Milestones

  1. Contribution of new evidence on the cardioprotective effect (acute myocardial infarction) of allopurinol and its link with the level of uricemia reached after treatment. Cardioprotection is strongly dependent on the duration of treatment and the level of uricemia (only observed when the level reached is less than 7mg/dL). The effect is observed in patients with gout and, to a lesser extent, in patients with asymptomatic hyperuricemia.
  2. New line of research in collaboration with the Cardiology Service of the Príncipe de Asturias U. Hospital, the Community of Madrid (Infarct Code) and the Institute of Environmental Diagnosis and Water Studies (IDEA) of the CSIC to evaluate the relationship between environmental factors (temperature, flu, contaminants,...) and acute myocardial infarction. The first result of this was an ecological study which showed that heat waves did not increase the risk of acute myocardial infarction in Madrid, but cold temperatures did.
  3. Collaboration with CEIFE in a population-based study to identify the predictors of over-anticoagulation in patients treated with AVK Renal function and indication were the most strongly associated factors.
  4. Estimation of the specific incidences of Toxic Epidermal Necrolysis of 13 active ingredients with a new methodological approach that combines data from a register with those of a population database.
  5. Contribution of information on the chemoprotective effect of NSAIDs in colorectal cancer, with the largest epidemiological study published to date. Analysis of 12 individual NSAIDs, all sharing the chemoprotective effect, regardless of their degree of COX-2 selectivity. Concomitant use of PPIs does not reduce the chemoprotective effect of NSAIDs

Bibliometrics

  Articles Accum. FI Mean  Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2018 6 22,08 3,68 6 100 2 33
2019 10 47,08 4,71 9 90 5 50
2020 9 87,17 9,69 9 67 1 11
2021 3 18,55 6,18 3 100 2 67
2022 11 62,89 5,72 9 82 2 18
  39 237,77 5,99 33 87,70 12 35,86

Networks and alliances